Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.

Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Böhm M.

Eur Heart J. 2017 Jan 7;38(2):93-100. doi: 10.1093/eurheartj/ehw325.

3.

An online spaced-education game among clinicians improves their patients' time to blood pressure control: a randomized controlled trial.

Kerfoot BP, Turchin A, Breydo E, Gagnon D, Conlin PR.

Circ Cardiovasc Qual Outcomes. 2014 May;7(3):468-74. doi: 10.1161/CIRCOUTCOMES.113.000814.

4.

Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.

Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):584-92. doi: 10.1111/jch.12133. Epub 2013 Jun 4.

5.

Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST study at 16 weeks.

Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Hiramatsu K, Kobayashi F, Shimada K.

J Hum Hypertens. 2013 Dec;27(12):721-8. doi: 10.1038/jhh.2013.68. Epub 2013 Jul 18.

6.

Type 2 diabetes in older people; the importance of blood pressure control.

Jindal A, Whaley-Connell A, Sowers JR.

Curr Cardiovasc Risk Rep. 2013 Jun;7(3):233-237.

8.

Atherosclerosis: current status of prevention and treatment.

Whayne TF Jr.

Int J Angiol. 2011 Dec;20(4):213-22. doi: 10.1055/s-0031-1295520.

9.

Blood pressure j-curve: current concepts.

Banach M, Aronow WS.

Curr Hypertens Rep. 2012 Dec;14(6):556-66. doi: 10.1007/s11906-012-0314-3. Review.

10.

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension.

Taylor AA, Ragbir S.

Patient Prefer Adherence. 2012;6:555-63. doi: 10.2147/PPA.S14764. Epub 2012 Aug 1.

11.

Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients.

Odili AN, Ezeala-Adikaibe B, Ndiaye MB, Anisiuba BC, Kamdem MM, Ijoma CK, Kaptue J, Boombhi HJ, Kolo PM, Shu EN, Thijs L, Staessen JA, Omotoso BA, Kingue S, Ba SA, Lemogoum D, M'Buyamba-Kabangu JR, Ulasi II.

Trials. 2012 May 17;13:59. doi: 10.1186/1745-6215-13-59.

12.

Vascular memory: can we broaden the concept of the metabolic memory?

Jermendy G.

Cardiovasc Diabetol. 2012 Apr 30;11:44. doi: 10.1186/1475-2840-11-44. Review.

13.

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

Judd E, Jaimes EA.

Expert Rev Cardiovasc Ther. 2012 Mar;10(3):293-303. doi: 10.1586/erc.12.7. Review.

14.
15.

Optimal management of hypertension in elderly patients.

Acelajado MC.

Integr Blood Press Control. 2010;3:145-53. doi: 10.2147/IBPC.S6778. Epub 2010 Nov 11.

16.
17.

Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension.

Shehab A, Abdulle A.

BMC Cardiovasc Disord. 2011 Jan 11;11:3. doi: 10.1186/1471-2261-11-3.

18.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

19.

Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors.

Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, Spalletta G, di Iulio F, Pettenati C, Cravello L, Caltagirone C.

J Neurol. 2009 Aug;256(8):1288-95. doi: 10.1007/s00415-009-5116-4. Epub 2009 Apr 8.

20.

Supplemental Content

Support Center